Ac-225 Archives

Tag: Ac-225

Alpha particle-emitting isotopes are being investigated in radio-immunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium-225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukaemia. Also being trialled in Neuroendocrine Cancer. Also known as targeted alpha therapy.

Clinical Trials and Research225Ac, Ac-225, Advanced neuroendocrine cancer, Metastatic Neuroendocrine Cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), PRRT, Small cell lung cancer (SCLC), Targeted alpha-emitter therapy (TAT)

Clinical Trials – Targeted Alpha-Emitter PRRT RYZ101 (Ac225)

By Ronny Allan Sep 14, 2022 0 Comments

Update 11th January 2026 RayzeBio has a new trial with the product RYZ401 entitled Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. Click here NCT07165132. The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs (meningiomas get a mention in the clinical trial document). This is different to the original product below when this blog was created (now Phase 3 RYZ101) but it also for well differentiated NETs as per clinical trials…